精准医学引导下肝癌周围的亚临床癌灶研究进展
Progress in Subclinical Cancer Foci around Liver under the Guidance of Precision Medicine

作者: 郑作深 :江门市中心医院(中山大学附属江门医院)肿瘤科,广东 江门;

关键词: 原发性肝癌复发亚临床病灶治疗精准医学Primary Liver Cancer Recurrence Subclinical Lesions Treatment Precision Medicine

摘要:
精准医学临床分析,小肝癌手术切除、局部治疗或精确放疗共存缺陷,肿瘤完整被切除,肝癌周围亚临床癌灶“被遗漏”,是40余年小肝癌术后5年生存率没有提高的瓶颈。当前肝癌研究正处于十字路口。遵照精准医学原则,完整治疗原发癌灶(治疗方法较多),并治疗癌周亚临床癌灶 (方法仅有全肝移动条野放疗1项),才能减少复发转移。本文围绕能够控制肝癌周围亚临床病灶不规则分布范围的认识来分析全肝移动条野放疗、精确放疗和外科切除肝癌的优缺点,探索三者优势互补的多学科合作与综合治疗的新方案。

Abstract: Precision medicine clinical analysis, small liver cancer surgical resection, local treatment or accurate radiotherapy coexisting defects, the thing that tumor is being resected completely and the thing that subclinical cancer around liver cancer "is missing" are the bottleneck that make the survival rate after small liver cancer surgery for 5 years not increased for more than 40 years. At present, the research of liver cancer is at a crossroad. In accordance with the principles of the precision medicine, completely treating the primary tumor foci (there are many treatment methods) and also treating cancer weeks subclinical cancer lesions (there is only one method that is the whole liver mobile radiation therapy), can reduce the recurrence and the metastasis. In this paper, we focus on the understanding that can control the range of the irregular distribution of the subclinical focus around the liver cancer to analyze advantages and disadvantages of the whole liver moving strip field radiotherapy, precise radiotherapy and surgical resection of the liver cancer, and explores the new scheme of multidisciplinary cooperation and comprehensive treatment that the advantages of three therapies supplement each other.

文章引用: 郑作深 (2016) 精准医学引导下肝癌周围的亚临床癌灶研究进展。 亚洲肿瘤科病例研究, 5, 45-54. doi: 10.12677/ACRPO.2016.53005

参考文献

[1] 郑荣寿, 左婷婷, 曾红梅, 等. 中国肝癌死亡状况与生存分析[J]. 中华肿瘤杂志, 2015, 37(9): 697-702.

[2] 樊嘉, 史颖弘. 精准医学引导下的肝脏外科[J]. 中华医学杂志, 2015, 95(31): 2500-2502.

[3] 汤钊猷. 试论中国肝癌防治之路[J]. 中华肿瘤杂志, 2015, 37(9): 641-643.

[4] 孙文兵. 肝癌患者出院后别忽视科学随访[J]. 中华养生保健, 2015(5): 27-28.

[5] 中华人民共和国卫生部[卫办医政改(2011)121号]. 原发性肝癌诊疗规范(2011版)[J]. 临床肿瘤学杂志, 2011, 6(10): 929-946.

[6] Fox, J.L. (2015) Obama Catapults Patient-Empowered Precision Medicine. Nature Biotechnology, 33, 325.
http://dx.doi.org/10.1038/nbt0415-325

[7] 张同琳, 马少华, 修典荣, 等. 原发性肝癌全肝切除标本的病理解剖学特征及其启示[J]. 中华外科杂志, 2010, 48(13): 964-967.

[8] 丛文铭, 董辉, 王斌, 等. 复发性肝癌临床病理特点与发生方式探讨[J]. 中国实用外科杂志, 2009, 29(1): 71-73.

[9] Shi, M., Zhang, C.Q., Zhang, Y.Q., et al. (2004) Micrometastases of Solitary Hepatoeellular Carcinoma and Appropriate Resection Margin. World Journal of Surgery, 28, 376-381.
http://dx.doi.org/10.1007/s00268-003-7308-x

[10] 石明, 张昌卿, 冯凯涛, 等. 肝细胞癌周围微转移分布的研究[J]. 中华肿瘤杂志, 2002, 24(3): 257-260.

[11] 徐彬, 李强, 付丽, 等. 肝细胞癌肝内微转移的研究[J]. 中华普通外科杂志, 2006, 21(8): 577-579.

[12] Nishikawa, H., Inuzuka, T., Takeda, H., et al. (2011) A Case of Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombus Refractory to Epirubicin That Showed Marked Decrease in Tumor Markers after Transcatheter Arterial Infusion with Miriplatin. Case Reports in Oncology, 4, 327-335.
http://dx.doi.org/10.1159/000330106

[13] Lu, X.Y., Xi, T., Lou, W.Y., et al. (2010) Palhobiological Fealures of Small Hapatocallalar Cacinoma: Correlation between Tumor Size and Biological Behavior. Journal of Cancer Research and Clinical Oncology, 137, 567-575

[14] Uka, K., Aikata, T., Karikomi, M., et al. (2007) Clinical Features and Prognosis of Patients with Extrahepatic mEtastases from Hepatocellular Carcinoma. World Journal of Gastroenterology, 19, 414-420.

[15] Toyoda, H., Fukuda, Y., Koyama, Y., Koyama, Y., et al. (1996) Case Report: Multiple Systemic Lymph Node Metastases from a Small Hepatocellular Carcinoma. Journal of Gastroenterology and Hepatology, 11, 959-962.
http://dx.doi.org/10.1111/j.1440-1746.1996.tb01854.x

[16] Kojiro, M. (1997) Pathology. In: Livraghi, T., Makuuchi, M. and Buscarini, L., Eds., Diagnosis and Treatment of Hepatocellular Carcinoma, Greenwich Medical Media, London, 35.

[17] 杨华, 郑勤. 肝癌放射治疗进展[J]. 东南大学学报(医学版), 2012, 31(4): 488-491.

[18] Zheng, Z.S., Zou, Y.H., Rao, J., et al. (2005) 460 Cases of Radiotherapy for Primary Massive Liver Cancer. Journal of US-China Medical Science, 2, 16-21.

[19] 郑作深. 放射治疗有可能成为治疗肝癌复发的新思路[J]. 世界肿瘤杂志, 2013, 3(3): 17-23.

[20] 郑作深. 巨大肝癌术前放疗5例长期随访的启示[J]. 国际病例报告, 2014, 1(2): 5-11.

[21] 郑作深, 吴庭安, 饶建, 等. 关于“移动条野放疗无论从理论还是实践, 都存在严重缺陷”的商榷[J]. 亚洲肿瘤科病例研究, 2014, 3(3): 25-36.

[22] Intemational Commission on Radiation Units and Measurements (1999) ICRU Report 62: Prescribing, Recording, and Reporting Photonbeam Therapy (Supplement to ICRU Report 50). 4-13.

[23] 于金明, 袁双虎. 肿瘤放疗的发展与挑战[J]. 山东大学学报(医学版), 2011, 49(10): 48-50.

[24] 贾明. 三维适形放疗治疗原发性小肝癌的临床研究[J]. 中国医药指南, 2013, 11(12): 182-183.

[25] Imada, H., Kato, H., Yasuda, S., et al. (2010) Comparison of Efficacy and Toxicity of Short Course Carbon Ion Radiotherapy for Heap to Cellular Carcinoma Depending on Their Proximity to the Porta Hepatis. Radiotherapy & Oncology, 96, 231-235.
http://dx.doi.org/10.1016/j.radonc.2010.05.019

[26] 肖平, 贾少微. 中国质子, 重离子放疗装置建设现状[J]. 罕少疾病杂志, 2014, 21(2): 1-5.

[27] 秦颖. 上海质子重离子医院目前每个疗程平均费用227.8万元[N]. 解放日报, 2015-5-9.

[28] 蒋国梁. 质子重离子放疗——一把“利刃”向肿瘤[J]. 抗癌, 2015, 28(2): 1-3.

[29] 蒋国梁. 质子重离子放疗的放射生物学[C]//复旦大学附属肿瘤医院. 第七届上海国际放射肿瘤学会议论文集. 上海, 2013.

[30] 蒋国梁. 肿瘤的质子和重离子放疗[C]//中华医学会, 中国抗癌协会. 中华医学会放射肿瘤治疗分会六届二次会议论文集. 济南, 2009.

[31] 蒋国梁. 肿瘤的质子和重离子放疗[C]//中华肿瘤杂志编辑部. 第二届肿瘤多学科综合诊治新概念学术研讨会论文集. 三亚, 2011..

[32] 蒋国梁. 肿瘤的质子和重离子放疗[C]//中华医学会. 中华医学会第九次全国放射肿瘤学学术会议论文集. 北京, 2012.

[33] 蒋国梁. 肿瘤的质子和重离子放疗[C]//中华医学会肿瘤学分会, 中国抗癌协会. 第五届中国肿瘤学术大会暨第七届海峡两岸肿瘤学术会议、国际肿瘤细胞与基因治疗学术会议、第二届中日肿瘤介入治疗学术会议论文集. 石家庄, 2008.

[34] 中华医学会器官移植学分会中华医学会外科学分会移植学组, 中国医师协会器官移植医师分会. 中国肝癌肝移植临床实践指南[J]. 中华外科杂志, 2014, 52(10): 721-725.

[35] 何勇勇, 石洁, 程树群. 原发性肝癌门静脉癌栓患者合并肝门淋巴结转移手术疗效的比较研究[J]. 中国微创外科杂志, 2012, 12(8): 687-689.

[36] 黄洁夫. 肝移植治疗原发性肝癌的现状及前景[J]. 肝胆外科杂志, 1999, 7(3): 163-165.

[37] 曾昭冲. 消融治疗后复发肝癌及肝外转移的放射治疗[J]. 中华医学杂志, 2015, 95(27): 2164-2166.

分享
Top